Results 141 to 150 of about 9,605 (202)

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab. [PDF]

BMJ Neurol Open
Høgestøl EA, Brustad ÅW, Celius EG, Meling M, Berg-Hansen P, Kro GB, König M, Schanke Y, Halvorsen B, Warren DJ, Gehin JE, Bolstad N, Nygaard GO.   +12 more
europepmc   +1 more source

Navigating the Transition: A Scoping Review of System-Level Factors in Biosimilar Integration for Immune-Mediated Inflammatory Diseases. [PDF]

BioDrugs
Kumar S, Dalbeth N, Gasteiger C.
europepmc   +1 more source

The FDA's adoption of Bayesian methodology: transforming clinical trial justification from biosimilars to broader drug development. [PDF]

Front Med (Lausanne)
Niazi SK.
europepmc   +1 more source

Demonstrating interchangeability and biosimilarity for US biosimilars [PDF]

Generics and Biosimilars Initiative Journal, 2016
openaire   +1 more source

Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? [PDF]

Pharmacoecon Open
Rodríguez-Lago I, Peinado-Fabregat JI, Guigini M, Cerezales M, Ibáñez F, Crespo C, Barreiro-de Acosta M.   +6 more
europepmc   +1 more source

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars. [PDF]

World J Gastroenterol
Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W, Bernatsky S.   +10 more
europepmc   +1 more source

BIOSIMILARS IN ONCOLOGY – PART I: THE PRINCIPLES OF BIOSIMILARS

Belgian Journal of Medical Oncology, 2020
Moorkens, Evelien, Vandenplas, Yannick, barcina, Teresa, Barbier, Liese, Vulto, Arnold   +4 more
openaire   +2 more sources

Biosimilar [PDF]

, 2020
openaire   +1 more source

Correction: Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]

Front Public Health
Hamida JA, Alkhatib NS, Hammour KA, Halloush S, Kurdi A, Balkhi B, Alfayez OM, Mousa R.   +7 more
europepmc   +1 more source

Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development. [PDF]

Biologics
Ranbhor R, Kulkarni P.
europepmc   +1 more source